Harmony Biosciences Holdings, Inc. (HRMY) Stock Price & How to Invest

Harmony Biosciences Holdings is a commercial-stage neuroscience company based in Plymouth Meeting, Pennsylvania, that licensed pitolisant from the French firm Bioprojet in 2017 and brought it to the U.S. market as WAKIX in 2019. WAKIX is a histamine H3 receptor antagonist and inverse agonist, and it is the only FDA-approved narcolepsy treatment that is not a scheduled controlled substance, which matters commercially because prescribers and patients avoid the paperwork and stigma attached to oxybate and stimulant options. Approvals have widened over time: excessive daytime sleepiness in adults in 2019, cataplexy in adults in 2020, and pediatric patients aged six and up in 2024 and 2026. The company reports a single segment, sells only in the United States, and had roughly 8,950 average patients on therapy in the second quarter of 2026 against a U.S. diagnosed narcolepsy population it estimates at about 80,000.

The investment picture turns on a countdown. WAKIX generated ~$261.3M in Q2 2026, up 30% year over year in its seventh year on the market, and the company reiterated full-year guidance of ~$1.0B to ~$1.04B. Trailing twelve-month revenue is ~$959.9M with ~$181.3M of net income and ~$3.09 in diluted EPS, so the shares change hands near 12 times earnings, which is closer to how the market prices a specialty pharma in run-off than a company growing 30%. Harmony's own IP disclosure supports WAKIX exclusivity to March 2030 including a six-month pediatric extension, and six of the seven generic filers have settled to license dates in 2030. Against that, the company is spending its cash flow on a pitolisant franchise extension (a gastro-resistant formulation with an April 2027 PDUFA date, a high-dose version in Phase 3, and a Phase 3 trial in Prader-Willi syndrome), on the orexin-2 receptor agonist BP-205, and on clemizole in rare epilepsies. Whether any of that replaces WAKIX revenue is the whole question, and none of the pivotal readouts land before 2027.

One product carries the entire company, and its exclusivity has a date on it: WAKIX runs to March 2030 including the pediatric extension, and six of the seven ANDA filers (Lupin, Novugen, Novitium, Hikma, Annora and MSN) have already settled to license dates in 2030, which makes generic entry scheduled rather than hypothetical. The seventh filer, AET Pharma US, is still litigating in the District of Delaware; a bench trial concluded in February 2026, post-trial briefing is complete, and closing arguments are set for October 22, 2026, with an adverse ruling capable of pulling that date forward. Harmony and Novitium filed a separate infringement suit against AET and its marketing partner Sandoz in April 2026 over the amorphous pitolisant patent (case 26-cv-00453-JLH), and the defendants answered in June with antitrust counterclaims, which introduces a liability the company was not previously carrying. Competitively, the oral orexin agonists in late-stage development at Takeda and Alkermes target the underlying deficiency in narcolepsy type 1 rather than the symptom, and if they reach the market with strong efficacy they could compress WAKIX before its patents expire. Two smaller items are worth noting: gross margin fell from 81.0% to 75.8% year over year on new Novitium royalties, and the CFO departed in July 2026 with an interim officer in place while the search runs.

10 analysts publish price targets on HRMY, averaging $46.10 against a $38.12 price as of August 2026, or +20.9%. The published targets run from $30.00 to $70.00, a wide spread, and the ratings split 6 buy, 3 hold, 1 sell. Over the last six months there have been 5 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full HRMY forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Harmony Biosciences Holdings, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. WAKIX is still accelerating in year seven. Second-quarter net product revenue of ~$261.3M grew 30% year over year, and average patients rose by ~450 in the quarter, the second-largest quarterly patient gain the company has reported. The most optimistic published target, $70.00, assumes this works close to its best case.

The case against. One product carries the entire company, and its exclusivity has a date on it: WAKIX runs to March 2030 including the pediatric extension, and six of the seven ANDA filers (Lupin, Novugen, Novitium, Hikma, Annora and MSN) have already settled to license dates in 2030, which makes generic entry scheduled rather than hypothetical. The most pessimistic target, $30.00, is roughly what HRMY is worth if this bites instead.

Read the full bull and bear case on HRMY, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Harmony Biosciences Holdings, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$959.9M, all from WAKIX
• Net income (TTM): ~$181.3M
• Diluted EPS (TTM): ~$3.09
• P/E (trailing): ~12x on a ~$2.22B market cap
• Cash and investments: ~$962.5M vs ~$160M debt (June 30, 2026)
• 2026 revenue guidance: ~$1.00B to ~$1.04B, reiterated August 2026

Netting out the balance sheet leaves an enterprise value near $1.4B against ~$960M of trailing revenue and ~$181M of net income, which is roughly 1.5 times sales and under 8 times earnings for a business growing 30%. That gap is not an oversight by the market; it is the discount attached to a single product with a 2030 expiry date and a live patent case. Whether the multiple is cheap or correct depends entirely on how much of the pipeline lands, and the first pivotal readouts do not arrive until 2027.

Other names that sit close to HRMY: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get HRMY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so HRMY sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where HRMY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Harmony is a rare thing in biotech, a company with real earnings and net cash, priced cheaply because one drug pays for everything and its exclusivity has a date on it.

Whether HRMY is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is HRMY a buy or a sell?, and where the stock could go from here in the HRMY stock forecast.

For income investors, whether HRMY pays a dividend and how the payout looks is covered in does HRMY pay a dividend? And to weigh HRMY against a peer, read the full side-by-side comparisons: HRMY vs JAZZ and HRMY vs ALKS.